E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers M > Headlines for Millennium Pharmaceuticals, Inc. > News item
Published on 4/6/2006 in the Prospect News Biotech Daily.

Millennium, Crucell sign agreement for production of monoclonal antibodies

By Elaine Rigoli

Tampa, Fla., April 6 - Crucell NV announced Thursday that it has signed a non-exclusive STAR research license agreement for the production of monoclonal antibodies with Millennium Pharmaceuticals Corp.

Financial details were not disclosed.

Millennium is a biotechnology company based in Cambridge, Mass.

Crucell is a biotechnology company based in Leiden, The Netherlands.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.